imeik technology development (300896.SZ): As of now, the company's products and services have not yet applied AI technology.

On December 10, Glonghui announced that imeik technology development (300896.SZ) stated on the investor interaction platform that as of now, the company's products and services have not applied AI technology.

Gelonghui FinanceDec 10 15:24

Express News | imeik technology development: The subsidiary has received approval for clinical trials of recombinant hyaluronidase injection.

BreakingsDec 6 18:20

Express News | China Merchants: imeik technology development continues to advance product research and development, enhance market competitiveness, and maintain a "shareholding" rating.

BreakingsNov 21 15:08

imeik technology development (300896): Hey body continues its steady growth, layouts food-grade and builds C-end capabilities.

The company's performance is steadily growing, with some adjustments to the product structure, and Meditech continues to grow steadily; the company's medical sodium hyaluronate gel containing polyethylene alcohol cross-linked microspheres has obtained a medical instrument registration certificate, suitable for adult subcutaneous injection filling to improve light and medium

china merchantsNov 20 00:00

Research reports dig deep into the third quarter, with imeik technology development maintaining good profitability and maintaining a "buy" rating.

Gelonghui November 11th | Changjiang Securities research report pointed out that it is expected that imeik technology development (300896.SZ) will experience a slowdown in revenue growth in 2024Q3 due to end demand, but overall still maintains good profitability. Overall, the company has kept the relative stability of the operating profit margin, with a quarterly growth rate of about 2% in net income attributable to the parent, slightly faster than the revenue growth rate. Currently, the company's Hi series products have established a good consumer mind share, and are expected to continue to benefit from the ongoing trend of light medical beauty consumption and compliant operation trends; at the same time, the joint application of Rubai Angel and Reway Angel is expected to continue to solidify the high-end price range, while various future potential benefits

Gelonghui FinanceNov 11 15:47 · Ratings

imeik technology development (300896): Income growth slows down, maintaining good profitability in the third quarter.

The company disclosed its third quarter report for 2024, with a revenue of 0.719 billion yuan in the third quarter alone, an increase of 1.1% year-on-year, and a net income attributable to shareholders of 0.465 billion yuan, an increase of 2.13% year-on-year. Comments on the event 2024Q3.

Changjiang SecuritiesNov 10 20:32